OPKO Health, Inc. OPK R2KR3KPHARMA
Company Overview
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
Why Investors Should Care
Revenue has grown at a 38.8% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.34.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $606.88M (-14.9% YoY); net profit $-225.68M.
- Trailing 12 Months Year-on-year growth — revenue +4.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 38.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 38.84% |
| 1 Year: | 4.30% |
Stock Price Performance
| 1 Year: | +21.48% |
| 6 Months: | +38.98% |
| 3 Months: | +13.89% |
| 1 Month: | +24.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)66.28 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 38.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OPK OPKO Health, Inc. R2KR3KPHARMA | 1.64 | -23.43 | $1.22B | 0.00% | -12.27% | -5.88% | 38.84% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 266.38M | 292.60M | 246.04M | 160.98M | 254.91M | 263.69M | 249.81M | 221.85M | 222.45M | 226.37M | 228.77M | 224.34M | 211.47M | 301.21M | 428.06M | 494.68M | 545.16M | 442.41M | 385.81M | 401.33M | 329.22M | 309.89M | 179.74M | 185.34M | 237.58M | 265.42M | 178.59M | 181.91M | 173.69M | 182.19M | 173.63M | 183.64M | 149.95M | 156.81M | 151.67M | 148.45M | 124.20M | 163.58M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.07M | 51.65M | 40.13M | - | 42.62M | 49.40M | 49.89M | - | 45.76M | 80.02M |
| Operating Income | -23.62M | - | -45.22M | -25.83M | -47.77M | - | -42.61M | -5.11M | -33.46M | - | -75.32M | -47.26M | -39.01M | - | -40.76M | 27.18M | 21.94M | - | 38.44M | 5.57M | 37.83M | - | -72.42M | -10.74M | -87.82M | - | -30.59M | 7.03M | -64.41M | - | -71.47M | -61.67M | -67.17M | - | -67.17M | -59.98M | 48.06M | - | -51.02M | -6.97M |
| Net Income | - | - | - | - | - | - | -43.11M | -6.20M | -27.66M | -76.07M | -80.76M | -59.81M | -62.01M | -112.35M | -59.13M | 33.70M | 23.72M | 32.30M | 31.08M | -16.19M | 28.74M | -73.78M | -55.43M | -101.65M | -86.09M | -85.23M | -18.27M | -19.64M | -84.47M | -66.48M | -81.84M | -10.30M | 24.89M | 14.03M | -67.61M | -148.44M | 21.63M | -31.26M | -54.85M | -8.42M |
| Diluted EPS | -0.03 | -0.04 | -0.06 | -0.04 | -0.06 | -0.39 | - | -0.01 | - | - | - | - | - | - | -0.09 | 0.05 | 0.04 | 0.05 | 0.05 | -0.03 | 0.04 | -0.11 | -0.08 | -0.14 | -0.11 | -0.11 | -0.02 | - | -0.11 | - | -0.12 | -0.01 | 0.03 | 0.01 | -0.10 | -0.19 | 0.03 | -0.04 | -0.07 | -0.01 |
| R&D Expense | 24.42M | - | 26.56M | 33.13M | 32.51M | - | 32.89M | 29.21M | 30.16M | - | 36.53M | 28.29M | 30.02M | - | 21.76M | 17.61M | 18.49M | - | 19.32M | 18.22M | 18.31M | - | 18.31M | 17.25M | 18.79M | - | 32.60M | 18.16M | 19.43M | - | 21.94M | 24.08M | 28.77M | - | 30.84M | 30.34M | 30.08M | - | 29.20M | 33.17M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.42M | 28.49M | 27.98M | 47.04M | 96.53M | 91.12M | 491.74M | 1.12B | 966.01M | 990.27M | 901.93M | 1.44B | - | 1.00B | 863.50M | 713.14M | 606.88M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 715.98M | 545.37M | 494.63M | 400.94M |
| Gross Profit | 1.54M | 15.00M | 10.74M | 19.17M | - | - | - | - | - | - | - | - | - | 288.22M | 318.13M | 218.51M | 205.94M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 534.34M | 476.18M | 492.07M | 424.93M |
| Operating Income | -22.15M | -11.14M | -23.19M | -37.27M | -79.63M | -145.81M | -98.48M | -96.55M | -276.44M | -171.20M | -274.05M | 57.71M | - | -246.12M | -158.06M | -273.56M | -218.99M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -270.81M | -65.52M | 135.28M | -41.27M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.06M | 13.51M | 47.47M | 108.46M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -391.52M | -184.32M | -10.36M | -241.36M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | -63.50M | 4.44M | 42.84M | -15.71M |
| Net Income | -30.11M | -18.93M | -1.28M | -29.05M | -114.41M | -171.67M | -30.03M | -48.36M | -305.25M | -153.04M | -314.93M | 30.59M | - | -328.40M | -188.86M | -53.22M | -225.68M |
| Diluted EPS | - | - | - | - | - | - | - | -0.10 | -0.55 | -0.27 | -0.53 | 0.05 | - | -0.46 | -0.25 | -0.08 | -0.30 |
| R&D Expense | 10.84M | 5.95M | 11.35M | 19.52M | 53.90M | 83.57M | 99.49M | 113.87M | 126.44M | 125.59M | 117.87M | 75.32M | 76.85M | 73.89M | 89.59M | 105.21M | 124.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 77.85M | 229.49M | 289.83M | 1.39B | 1.27B | 2.80B | 2.77B | 2.59B | 2.45B | 2.31B | 2.47B | 2.40B | 2.17B | 2.01B | 2.20B | 1.93B |
| Total Equity | 359.00K | 31.60M | 23.05M | 160.88M | 179.39M | 876.41M | 842.14M | 1.98B | 2.05B | 1.84B | 1.79B | 1.61B | 1.67B | 1.69B | 1.56B | 1.39B | 1.37B | 1.27B |
| Cash & Equivalents | 6.68M | 42.66M | 18.02M | 71.52M | 27.36M | 185.80M | 96.91M | 193.60M | 168.73M | 91.50M | 96.47M | 85.45M | 72.21M | 134.71M | 153.19M | 95.88M | 426.58M | 364.41M |
| Long Term Debt | - | - | - | - | 5.15M | 3.27M | 2.43M | 2.52M | 717.00K | 1.57M | 4.65M | 3.91M | 251.21M | 205.27M | 9.29M | 7.73M | 3.00M | 2.26M |
| Total Liabilities | - | - | 28.67M | 44.22M | 86.55M | 518.54M | 431.92M | 819.39M | 674.81M | 746.33M | 659.78M | 694.51M | 801.51M | 714.59M | 605.61M | 622.48M | 834.76M | 663.99M |
| Current Liabilities | - | - | 27.60M | 18.78M | 52.38M | 91.85M | 83.11M | 251.90M | 263.30M | 312.03M | 288.32M | 249.12M | 375.48M | 330.01M | 213.48M | 200.05M | 193.10M | 146.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.46M | -18.71M | -18.50M | -25.41M | -55.65M | -90.38M | 164.02M | 32.05M | -92.08M | -109.14M | -172.52M | 39.48M | 38.34M | -95.19M | -28.20M | -183.49M | -178.54M |
| Investing Cash Flow | -22.60M | -2.78M | -14.84M | -24.77M | 30.32M | -5.67M | -99.22M | -20.70M | -46.67M | -26.12M | -13.27M | -18.33M | 35.95M | 91.04M | -18.20M | 352.21M | 230.30M |
| Financing Cash Flow | 81.92M | -2.77M | 86.92M | 6.03M | 183.63M | 7.26M | 33.01M | -35.20M | 61.04M | 140.91M | 175.25M | -35.08M | -10.35M | 22.97M | -11.30M | 184.17M | -118.06M |
| Share Buybacks | - | - | 7.83M | 0 | 0 | - | - | - | - | - | - | - | - | 0 | 0 | 90.22M | 47.04M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 34.9% | 52.6% | 38.4% | 40.7% | - | - | - | - | - | - | - | - | - | 28.7% | 36.8% | 30.6% | 33.9% |
| Operating Margin % | -501.3% | -39.1% | -82.9% | -79.2% | -82.5% | -160.0% | -20.0% | -8.6% | -28.6% | -17.3% | -30.4% | 4.0% | - | -24.5% | -18.3% | -38.4% | -36.1% |
| Net Margin % | -681.6% | -66.4% | -4.6% | -61.7% | -118.5% | -188.4% | -6.1% | -4.3% | -31.6% | -15.5% | -34.9% | 2.1% | - | -32.7% | -21.9% | -7.5% | -37.2% |
| ROE % | -95.3% | -82.1% | -0.8% | -16.2% | -13.1% | -20.4% | -1.5% | -2.4% | -16.6% | -8.5% | -19.5% | 1.8% | - | -21.0% | -13.6% | -3.9% | -17.8% |
| ROCE % | - | -22.2% | -11.0% | -15.7% | -6.1% | -12.3% | -3.9% | -3.9% | -12.1% | -7.9% | -13.3% | 2.8% | - | -12.6% | -8.7% | -13.6% | -12.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Rubric Capital Management LP | 6.40% | 47.79M | $70.73M |
| 2 | Blackrock Inc. | 4.95% | 36.98M | $54.73M |
| 3 | Vanguard Capital Management LLC | 2.01% | 14.97M | $22.15M |
| 4 | Vanguard Portfolio Management LLC | 2.00% | 14.93M | $22.10M |
| 5 | Geode Capital Management, LLC | 1.55% | 11.58M | $17.14M |
| 6 | State Street Corporation | 1.38% | 10.31M | $15.26M |
| 7 | Goldman Sachs Group Inc | 0.94% | 7.04M | $10.41M |
| 8 | UBS Group AG | 0.67% | 5.01M | $7.41M |
| 9 | Whitefort Capital Management, LP | 0.60% | 4.51M | $6.68M |
| 10 | Northern Trust Corporation | 0.50% | 3.76M | $5.56M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OPK
$OPK stock is up 8% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxObGdMZ3l6N1lpdHlMdTUtemgweVUwQTlEMEd5ZEJEZmstZGRqSkR5ZF9IV2hpS3N1d05IQWZXa0Y5dHZ3OFl2cG94cHRuV1Q0M1BVRTU3TUk4TEJCSTJCSllsNnJyamMydGVubmFydktiR0lFa3F4elhqYlVzX19SMjNWLW1sWjBkS2hRY0…
Here's Why You Should Retain OPK Stock in Your Portfolio for Now - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQTFlWRGlUZE9LeFRuc3NsUUc2YXFmOEdobkFrMUhaNWtFNlFOR1pxWFlVR0RPNkJKSDdZOWVjaXFuOEplT0FnX0tmcU44LVIxRXZDSDJvMzJkcjh5OS1jQUp4M1lSVzBWb2t3Q2w5cHdGUU1fVklkZkU0YXRUUWFNRjZ0czIxOEFlN3ZlXy…
OPKO Health (OPK) Stock Looks Stretched On Fresh Royalty Backed Financing - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQeGNtOWlPWWZvTnhVWFFCSXllOXdla2tyME9tbEx3WVhaaE1vYXhvTC1ieGlmalZudHVDemNMZTBtTzhWSUpNaEdHTi02MFBvMW9OREtRcllIYTZwYTBuVW5YOFFxUi1NZTdPLTRTRmZMTDdRcmpLRXM2NHo4R1NINGk4YW4yTHUtd0ozcH…
OPKO Issues $125M Notes While Keeping Future Mazdutide Royalties - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOY05BNENhT29JemxrMFZ2dkk2dnZMSm1RbjRQdFZrR0p2UHFqeHZEWnlubDBaQm1RR0N4QnZHekE5VHBMNmVTWFdlaWE5QmhJeDNHRUY4UGh0T2c5Q0VOMTJWdjRfUlE4NFJzODlRSTZSVUlvM01EbzR4dVZsYjd2cy1pa19VaTJuVTFkMU…
OPK - Finviz
<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTFBHNGJXTGNmakZ3MU4xNWpqSE5VSGtScFdMVTVRekViaEFfa01MWE8taDd0NlJXZ1JIM184S2ozM29VbVphY2xzUUVVWDBtcnF5SS1ubmdMb3U5WXpoQXA5NlhkRmxOS3F0d0cxaUVlS0I1RjA?oc=5" target="_blank">OPK</a> …
OPKO Health: Mazdutide And MDX-2201 Could Change Everything (NASDAQ:OPK) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQSTZQTkRBd1B4Ylk4ejBYS1hzM1BPTXVHdEZOMEdHYVBtT1JOT3dMMUctVkY4SFdKc0t5RVZGQUdnWTB5d0xmYzRNTzZSRjRhcTAzQXlFX1JXemlScnRBNmhQQkVyeGU2eHU4a1ZTdHZQOUM5QTBPY2pPTzFsSXZGeVhMUURHUlZPdHd1bT…
OPK — Frequently Asked Questions
What is the current share price of OPKO Health, Inc. (OPK)?
As of 2026-09-07 16:24 PDT, OPKO Health, Inc. (OPK) trades at $1.64 on NasdaqGS. Its 52-week range is $1.10 to $1.69.
What is the market capitalisation of OPK?
OPKO Health, Inc. (OPK) has a market capitalisation of $1.22B on NasdaqGS.
What is the P/E ratio of OPK?
OPK trades at a trailing price-to-earnings (P/E) ratio of -23.43. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.86.
What is the return on equity (ROE) of OPK?
OPK has a return on equity (ROE) of -5.88%. Its return on capital employed (ROCE) is -12.27%.
Is OPK a good stock to buy?
This page provides a data-driven analysis of OPKO Health, Inc. (OPK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.